Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

MiR-492 as an Important Biomarker for Early Diagnosis and Targeted Treatment in Different Cancers

Author(s): Eskandar Taghizadeh, Forough Taheri, Daryoush Rostami, Pedram G. Renani , Gordon A. Ferns, Alireza Pasdar* and Majid G. Mobarhan*

Volume 16, Issue 4, 2020

Page: [269 - 275] Pages: 7

DOI: 10.2174/1573394716666200309124048

Abstract

Recent studies have led to a more detailed understanding of the roles played by microRNAs in health and disease, and their potential use as biomarkers in physiological and pathophysiological processes involving cancer initiation and progression. MiR-492 is encoded by a pseudogene, has a key role in some human cancer cells and its overexpression in tissues, and it has been proposed that it can be used as a good biomarker for management and early diagnosis of some cancers including breast cancer, colorectal and ovarian cancer, hepatocellular cancer, retinoblastoma and pancreatic cancer. The aim of this review was to summarize the data of MiR-492 for early diagnosis and treatment of some types of related cancers.

Keywords: MiR-492, breast cancer, microRNAs, colorectal cancer, RNA-silencing, biomarker.

« Previous Next »
Graphical Abstract

[1]
Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008; 9(3): 219-30.
[http://dx.doi.org/10.1038/nrm2347] [PMID: 18270516]
[2]
O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007; 104(5): 1604-9.
[http://dx.doi.org/10.1073/pnas.0610731104] [PMID: 17242365]
[3]
Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: Stepwise processing and subcellular localization. EMBO J 2002; 21(17): 4663-70.
[http://dx.doi.org/10.1093/emboj/cdf476] [PMID: 12198168]
[4]
Murchison EP, Hannon GJ. miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr Opin Cell Biol 2004; 16(3): 223-9.
[http://dx.doi.org/10.1016/j.ceb.2004.04.003] [PMID: 15145345]
[5]
Slezak-Prochazka I, Durmus S, Kroesen BJ, van den Berg A. MicroRNAs, macrocontrol: Regulation of miRNA processing. RNA 2010; 16(6): 1087-95.
[http://dx.doi.org/10.1261/rna.1804410] [PMID: 20423980]
[6]
Shukla GC, Singh J, Barik S. MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol 2011; 3(3): 83-92.
[PMID: 22468167]
[7]
Zhou X, Duan X, Qian J, Li F. Abundant conserved microRNA target sites in the 5′-untranslated region and coding sequence. Genetica 2009; 137(2): 159-64.
[http://dx.doi.org/10.1007/s10709-009-9378-7] [PMID: 19578934]
[8]
Martinelli-Boneschi F, Fenoglio C, Brambilla P, et al. MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett 2012; 508(1): 4-8.
[http://dx.doi.org/10.1016/j.neulet.2011.11.006] [PMID: 22108567]
[9]
Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell 2012; 149(3): 515-24.
[http://dx.doi.org/10.1016/j.cell.2012.04.005] [PMID: 22541426]
[10]
Wu T, Chen G. miRNAs participate in MS pathological processes and its therapeutic response. Mediat inflam 2016; 20164578230
[11]
Pandima Devi K, Rajavel T, Daglia M, Nabavi SF, Bishayee A, Nabavi SM. Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer. Semin Cancer Biol 2017; 46: 146-57.
[http://dx.doi.org/10.1016/j.semcancer.2017.02.001] [PMID: 28185862]
[12]
Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99(24): 15524-9.
[http://dx.doi.org/10.1073/pnas.242606799] [PMID: 12434020]
[13]
Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008; 105(36): 13556-61.
[http://dx.doi.org/10.1073/pnas.0803055105] [PMID: 18768788]
[14]
Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125(11): 2737-43.
[http://dx.doi.org/10.1002/ijc.24638] [PMID: 19521961]
[15]
von Frowein J, Pagel P, Kappler R, von Schweinitz D, Roscher A, Schmid I. MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. Hepatology 2011; 53(3): 833-42.
[http://dx.doi.org/10.1002/hep.24125] [PMID: 21319197]
[16]
Devor EJ. Primate microRNAs miR-220 and miR-492 lie within processed pseudogenes. J Hered 2006; 97(2): 186-90.
[http://dx.doi.org/10.1093/jhered/esj022] [PMID: 16489141]
[17]
Wang J, Raimondo M, Guha S, et al. Circulating microRNAs in pancreatic juice as candidate biomarkers of pancreatic cancer. J Cancer 2014; 5(8): 696-705.
[http://dx.doi.org/10.7150/jca.10094] [PMID: 25258651]
[18]
Yu D, Zhang Z, Glass K, et al. New statistical methods for constructing robust differential correlation networks to characterize the interactions among microRNAs. Sci Rep 2019; 9(1): 3499.
[http://dx.doi.org/10.1038/s41598-019-40167-8] [PMID: 30837613]
[19]
DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017; 67(6): 439-48.
[http://dx.doi.org/10.3322/caac.21412] [PMID: 28972651]
[20]
O’Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010; 12(2): 201.
[http://dx.doi.org/10.1186/bcr2484] [PMID: 20346098]
[21]
Lin MS, Chen WC, Huang JX, Gao HJ, Sheng HH. Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer. Int J Clin Exp Med 2014; 7(12): 5226-34.
[PMID: 25664025]
[22]
Janghorban M, Farrell AS, Allen-Petersen BL, et al. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. PNAS 2014; 111(25): 9157-62.
[http://dx.doi.org/10.1073/pnas.1317630111]
[23]
Yan L, Zheng M, Wang H. Circular RNA hsa_circ_0072309 inhibits proliferation and invasion of breast cancer cells via targeting miR-492. Cancer Manag Res 2019; 11: 1033-41.
[http://dx.doi.org/10.2147/CMAR.S186857] [PMID: 30774431]
[24]
Kupcinskas J, Bruzaite I, Juzenas S, et al. Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer. Sci Rep 2014; 4: 5993.
[http://dx.doi.org/10.1038/srep05993] [PMID: 25103961]
[25]
Li X, Zhang G, Luo F, et al. Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep 2012; 28(1): 77-84.
[PMID: 22576798]
[26]
Lee HC, Kim JG, Chae YS, et al. Prognostic impact of microRNA-related gene polymorphisms on survival of patients with colorectal cancer. J Cancer Res Clin Oncol 2010; 136(7): 1073-8.
[http://dx.doi.org/10.1007/s00432-009-0754-6] [PMID: 20044760]
[27]
Slaby O, Bienertova-Vasku J, Svoboda M, Vyzula R. Genetic polymorphisms and microRNAs: New direction in molecular epidemiology of solid cancer. J Cell Mol Med 2012; 16(1): 8-21.
[http://dx.doi.org/10.1111/j.1582-4934.2011.01359.x] [PMID: 21692980]
[28]
Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J 2012; 18(3): 244-52.
[http://dx.doi.org/10.1097/PPO.0b013e318258b78f] [PMID: 22647361]
[29]
Peng L, Zhu H, Wang J, et al. MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147. Mol Cell Biochem 2015; 405(1-2): 73-9.
[http://dx.doi.org/10.1007/s11010-015-2397-z] [PMID: 25862460]
[30]
Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 2008; 68(7): 2530-7.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-5991] [PMID: 18381463]
[31]
Jiang J, Zhang Y, Yu C, Li Z, Pan Y, Sun C. MicroRNA-492 expression promotes the progression of hepatic cancer by targeting PTEN. Cancer Cell Int 2014; 14(1): 95.
[http://dx.doi.org/10.1186/s12935-014-0095-7] [PMID: 25253996]
[32]
Nakahata S, Ichikawa T, Maneesaay P, et al. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat Commun 2014; 5: 3393.
[http://dx.doi.org/10.1038/ncomms4393] [PMID: 24569712]
[33]
Yu G, Xiao Q, Ma XP, et al. miR-492G>C polymorphism (rs2289030) is associated with overall survival of hepatocellular carcinoma patients. Tumour Biol 2016; 37(7): 8961-72.
[http://dx.doi.org/10.1007/s13277-015-4752-9] [PMID: 26753964]
[34]
von Frowein J, Hauck SM, Kappler R, et al. MiR-492 regulates metastatic properties of hepatoblastoma via CD44. Liver Int 2018; 38(7): 1280-91.
[http://dx.doi.org/10.1111/liv.13687] [PMID: 29314711]
[35]
Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4(1): 33-45.
[http://dx.doi.org/10.1038/nrm1004] [PMID: 12511867]
[36]
Li J, Liu Q, Clark LH, Qiu H, Bae-Jump VL, Zhou C. Deregulated miRNAs in human cervical cancer: functional importance and potential clinical use. Future Oncol 2017; 13(8): 743-53.
[http://dx.doi.org/10.2217/fon-2016-0328] [PMID: 27806630]
[37]
Taghizadeh E, Taheri F, Abdolkarimi H, Ghorbani Renani P, Gheibi Hayat SM. Distribution of human papillomavirus genotypes among women in Mashhad, Iran. Intervirology 2017; 60(1-2): 38-42.
[http://dx.doi.org/10.1159/000477848] [PMID: 28723690]
[38]
Liu M, An J, Huang M, et al. MicroRNA-492 overexpression involves in cell proliferation, migration, and radiotherapy response of cervical squamous cell carcinomas. Mol Carcinog 2018; 57(1): 32-43.
[http://dx.doi.org/10.1002/mc.22717] [PMID: 28802022]
[39]
Liu M, Wang Z, Liu Q, Zhu H, Xu N. Expression of micro-RNA-492 (MiR-492) in human cervical cancer cell lines is upregulated by transfection with wild-type P53, irradiation, and 5-Fluorouracil treatment in vitro. Med Sci Monit 2018; 24: 7750-8.
[http://dx.doi.org/10.12659/MSM.911585] [PMID: 30374014]
[40]
Nambaru L, Meenakumari B, Swaminathan R, Rajkumar T. Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pac J Cancer Prev 2009; 10(3): 355-60.
[PMID: 19640172]
[41]
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014; 384(9951): 1376-88.
[http://dx.doi.org/10.1016/S0140-6736(13)62146-7] [PMID: 24767708]
[42]
Braicu O-L, Budisan L, Buiga R, et al. miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples. OncoTargets Ther 2017; 10: 4225-38.
[http://dx.doi.org/10.2147/OTT.S137107] [PMID: 28894379]
[43]
Zhao J-J, Yang J, Lin J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 2009; 25(1): 13-20.
[http://dx.doi.org/10.1007/s00381-008-0701-x] [PMID: 18818933]
[44]
Thériault BL, Dimaras H, Gallie BL, Corson TW. The genomic landscape of retinoblastoma: A review. Clin Exp Ophthalmol 2014; 42(1): 33-52.
[http://dx.doi.org/10.1111/ceo.12132] [PMID: 24433356]
[45]
Sun Z, Zhang A, Zhang L. Inhibition of microRNA-492 attenuates cell proliferation and invasion in retinoblastoma via directly targeting LATS2. Mol Med Rep 2018; 2018: 1965-71.
[http://dx.doi.org/10.3892/mmr.2018.9784]
[46]
Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362(17): 1605-17.
[http://dx.doi.org/10.1056/NEJMra0901557] [PMID: 20427809]
[47]
Słotwiński R, Lech G, Słotwińska SM. MicroRNAs in pancreatic cancer diagnosis and therapy. Cent Eur J Immunol 2018; 43(3): 314-24.
[http://dx.doi.org/10.5114/ceji.2018.80051] [PMID: 30588176]
[48]
Schultz NA, Werner J, Willenbrock H, et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol 2012; 25(12): 1609-22.
[http://dx.doi.org/10.1038/modpathol.2012.122] [PMID: 22878649]
[49]
Zhou X, Huang Z, Xu L, et al. A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget 2016; 7(43): 69616-24.
[http://dx.doi.org/10.18632/oncotarget.11903] [PMID: 27626307]
[50]
Baradaran B, Shahbazi R, Khordadmehr M. Dysregulation of key microRNAs in pancreatic cancer development. Biomed Pharmacother 2019; 109: 1008-15.
[http://dx.doi.org/10.1016/j.biopha.2018.10.177] [PMID: 30551350]

Rights & Permissions Print Cite
Article Metrics
53
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy